Skip to main content

Table 4 Relative risk of hearing loss of amikacin and kanamycin use in MDR-TB treatment

From: Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort

 

Any hearing loss Crude OR (95 % CI)

Any hearing loss aaOR (95 % CI)

Less severe hearing loss aaOR (95 % CI)

More severe hearing loss aaOR (95 % CI)

Kanamycin

Reference

Reference

Reference

Reference

Amikacin

2.3 (1.2–4.6)

2.3 (1.0–5.4)

1.6 (0.6–4.5)

4.0 (1.5–10.8)

  1. Legend: aOR adjusted odds ratio, aadjusted for patient age, treatment site and year of treatment initiation; 95%CI =95 % confidence interval. Note that baseline body weight band, sex, human immunodeficiency virus infection status were not adjusted for because they were potential effect-modifiers (see Table 5)